ReviewAtherosclerosis plus2024
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.
Review in Atherosclerosis plus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- The effect of Hp infection on dyslipidemia in Asia and out of Asia: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Effect of Different Dietary Patterns on Cardiometabolic Risk Factors: An Umbrella Review of Systematic Reviews and Meta-Analyses.Nutrients · 2024Pooled it
- Trial
- Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a).Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Diagnostic and Therapeutic Challenges in Statin-Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report.Clinical case reports · 2026Article
- Statin treatment in routine clinical practice: Insights from the STATRIP physician survey.Atherosclerosis plus · 2026Article
- Pleiotropic Effects of Statins: Focus on Endothelial Function, Plaque Stability and Thrombosis (Part II).Current atherosclerosis reports · 2026Review
- Novel drugs targeting genetic variants: current applications and future prospects in heart failure treatment.Frontiers in molecular biosciences · 2026Review
- Sodium, potassium intake and urinary sodium-to-potassium ratio in rheumatoid arthritis: association with markers of cardiovascular dysfunction and disease-related parameters.Clinical rheumatology · 2025Article
- Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a).Atherosclerosis plus · 2025Article
- Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?Pharmaceuticals (Basel, Switzerland) · 2025Review
- High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis.Archives of medical sciences. Atherosclerotic diseases · 2025Review
- Incorporating lipoprotein(a) into patient care: the Polish landscape in light of national recommendations and the updated ESC/EAS guidelines.Archives of medical science : AMS · 2025Article
- Prevalence and Risk Factors for Atherosclerotic Cardiovascular Disease in 7704 Individuals: An Analysis from the Greek Registry for the Prevalence of Familial Hypercholesterolemia (GRegistry-FH).Journal of cardiovascular development and disease · 2024Article
- Article
- The Association between Food Groups, Nutraceuticals, and Food Supplements Consumption on Vascular Health Outcomes: A Literature Review.Life (Basel, Switzerland) · 2024Review
- Residual cardiovascular disease risk in heart failure patients. What is the real role of lipid-lowering therapy?Archives of medical science : AMS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.